We describe the case of a 32‐year‐old female with MS and PFIC3 who was effectively treated with natalizumab and ursodeoxycholic acid (UCDA), in contrast to glatiramer acetate, dimethylfumarate, and IFNb1a associated with DILI. This evidence concerns the gene ABCB4 and myeloid sarcoma.